FDA accepted the New Drug Application (NDA) for encaleret from BridgeBio.
3 reports, 2 independent
Updated Oct 11
Gone quiet
- Reports
- 3
- Developments
- 2
- Repetition
- 33%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
FDA accepted the New Drug Application (NDA) for encaleret from BridgeBio.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Barclays issues overweight rating on BridgeBio, linking it to FDA review of BBP-418 and market size comparison to Nvidia.1 source
FDA accepted NDA for BridgeBio's encaleret.1 source
Keep exploring
The entities involved
Related events
- FDA approval supports NDA submission in Aurora.
- Takeda is seeking FDA approval for its drug ORZEYFUL.
- The FDA requested additional clinical data from Unicycive Therapeutics.
- Ascelia Pharma AB received a Complete Response Letter from the FDA regarding its NDA on July 3, 2026.
- FDA provided guidance for HCW Biologics' IND application.